rhuFlt3L/CDX-301 + Poly-ICLC
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Low-Grade B-cell Lymphoma
Conditions
Low-Grade B-cell Lymphoma
Trial Timeline
Jan 3, 2014 → Nov 20, 2020
NCT ID
NCT01976585About rhuFlt3L/CDX-301 + Poly-ICLC
rhuFlt3L/CDX-301 + Poly-ICLC is a phase 1/2 stage product being developed by Celldex Therapeutics for Low-Grade B-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01976585. Target conditions include Low-Grade B-cell Lymphoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01976585 | Phase 1/2 | Completed |
Competing Products
13 competing products in Low-Grade B-cell Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rabeprazole Sodium | Eisai | Pre-clinical | 23 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 52 |
| Everolimus | Novartis | Phase 2 | 52 |
| MEK162, MEK inhibitor; oral + Physician's choice chemotherapy | Pfizer | Phase 3 | 76 |
| Fludarabine Phosphate (Fludara) + Rituximab | Sanofi | Phase 2 | 51 |
| rituximab | Biogen | Phase 3 | 74 |
| Tovorafenib | Ipsen | Phase 1 | 30 |
| Tovorafenib | Day One Biopharmaceuticals | Phase 2 | 47 |
| Tovorafenib + Chemotherapeutic Agent | Day One Biopharmaceuticals | Phase 3 | 72 |
| DAY101 | Day One Biopharmaceuticals | Phase 1 | 28 |
| Tovorafenib | Day One Biopharmaceuticals | Pre-clinical | 18 |
| TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBD | Tyra Biosciences | Phase 2 | 47 |
| combined therapy with rh-ES and CV | Brain Biotech | Phase 2 | 44 |